Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS):
AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and 1.2Bil potential milestone payments Servier 40Mil upfront payment and 447Mil potential milestone payments inhaled program PRS-220 for the treatment of IPF. selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis
On 8/16/2021 Morgan Stanley reported 1,675,969 shares of PIRS for 6.42Mil, an increase of +104.6% for an ownership of 2.512% in the company
On 4/26/2021 HC Wainwright brokerage Reiterated Rating to Buy and a price target of $9.00
On 6/30/2021 Jefferies Financial Group brokerage Boosted Price Target to Buy from $6.00 to $8.00
Usually i have price targets lower than most analysts, but on PIRS, my price target is 10usd.
I`m looking forward to read your opinion about it.